title: First reported pediatric case of systemic lupus erythematosus associated with prolactinoma.
abstract: There is much interest in the possibility that prolactin influences disease activity in systemic lupus erythematosus (SLE). We present the first reported pediatric case of prolactinoma associated with SLE, in a 13-year-old white female. The diagnosis of SLE was based on the presence of arthritis, antinuclear antibodies, and double-stranded DNA, and a chest radiograph showing pleural fluid. The diagnosis of pituitary prolactinoma was based on the histologic features and the presence of amenorrhea, galactorrhea, and an elevated serum prolactin level. Neurosurgical resection and medical therapy with bromocriptine mesylate were independently associated with decreased prolactin levels, loss of arthritis, and reduced levels of inflammatory mediators.
authors.affiliation: Pediatric Rheumatology and Clinical Research, Children's Hospital Medical Center, One Perkins Square, Akron, OH 44308, USA. PReuman@CHMCA.org
authors.forename: Peter D
authors.initials: PD
authors.lastname: Reuman
mesh_terms: D000293:Adolescent; D001168:Arthritis / Q000209:etiology; D001971:Bromocriptine / Q000627:therapeutic use; D005260:Female; D006727:Hormone Antagonists / Q000627:therapeutic use; D006801:Humans; D018836:Inflammation Mediators / Q000097:blood; D008180:Lupus Erythematosus, Systemic / Q000097:blood / Q000150:complications* / Q000188:drug therapy; D010911:Pituitary Neoplasms / Q000150:complications* / Q000601:surgery; D011388:Prolactin / Q000097:blood; D015175:Prolactinoma / Q000150:complications* / Q000188:drug therapy / Q000601:surgery; D016896:Treatment Outcome
chemical_list: D006727:Hormone Antagonists; D018836:Inflammation Mediators; D001971:Bromocriptine; D011388:Prolactin